GlassScriptPhysician profile
Marc A Williams
NPI 1659542926
$4,822.30
in general payments reported to CMS, 2019-2025
39 companies · $689 in 2025
The $689 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,329 · 2022: $1,158 · 2023: $1,044 · 2024: $603 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $842.15 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $689.39 | 2021-2025 | |
| Amgen INC. | $509.19 | 2021-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $341.74 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $238.52 | 2021-2024 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.74 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Astellas Pharma US INC | $188.96 | 2023-2025 | Veozah |
| Pfizer INC. | $183.25 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.76 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $138.32 | 2022 | |
| Mylan Specialty L.P. | $136.21 | 2021-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $119.95 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $113.28 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $96.60 | 2021 | |
| Janssen Pharmaceuticals, INC | $81.04 | 2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $62.83 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $58.58 | 2024-2025 | Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $56.40 | 2023-2024 | Gemtesa |
| Inspire Medical Systems, INC. | $54.81 | 2023 | Inspire |
| Merck Sharp & Dohme LLC | $49.12 | 2021-2023 | Vaxneuvance, Gardasil 9, Rotateq |
| Aimmune Therapeutics, INC. | $45.45 | 2025 | Zenpep |
| Nevro Corp. | $44.70 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $43.20 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.75 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $38.30 | 2023-2024 | Glassia, Trintellix |
| Grifols USA, LLC | $34.02 | 2021-2024 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $33.44 | 2021 | |
| Cequr Corporation | $31.54 | 2024 | Cequr Simplicity |
| Eisai INC. | $29.17 | 2021 | |
| Stryker Corporation | $28.46 | 2023 | Blueprint Patient Specific Instrumentation, Universal Neuro 3 |
| Sanofi Pasteur INC. | $25.69 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $19.53 | 2021 | |
| Genentech USA, INC. | $18.02 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.38 | 2023 | Quviviq |
| Exeltis, USA INC. | $17.09 | 2023 | Slynd |
| Kowa Pharmaceuticals America, INC. | $15.33 | 2025 | Zoryve |
| Inogen, INC. | $14.53 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.94 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.